A clinical trial involving somatropin recombinant, registered as NCT00663611, was updated on August 7, 2026 to reflect a status change. The trial, titled "Growth Hormone Administration and the Human Immune System," is listed as a Phase 1 study. Its current status is marked as COMPLETED in the ClinicalTrials.gov registry.
Somatropin recombinant remains classified as unapproved for research use in this context. No results data, efficacy findings, or safety conclusions were included in this status update. The listing reflects only the trial's phase and completion status as recorded on the specified date.
This update does not indicate what outcomes, if any, were observed during the study. No specific findings related to immune system effects or other endpoints were disclosed in the event record reviewed here.
Readers interested in additional background may consult the compound overview for further context on somatropin recombinant.